Citation audit
Does every citation actually support its claim?
For each citation in the canonical live run: does the source exist, was it retrieved, and does the passage support the claim that cites it — checked deterministically by lexical overlap, not asserted by the model. See methods for this grader’s known blind spots.
68
Direct support
The cited passage directly states the claim (≥50% lexical overlap, a heuristic, not NLI).
2
Indirect support
The passage is topically related but doesn't directly state the claim (15–50% overlap).
0
No support
The cited passage does not support the claim at all.
0
Not retrieved
The document exists in the corpus but wasn't part of this run's retrieved set.
0
Source missing
The cited doc_id doesn't resolve to any document — a dangling or fabricated reference.
70 total citations across 3 architectures × 20 tasks
| Task | Architecture | Claim | Cited doc | Status |
|---|---|---|---|---|
| A1 | Baseline 1 · retrieve + synthesize | The canonical function of the p53 protein is as a tumor suppressor. | PMID:42701099 | Direct support |
| A1 | Baseline 1 · retrieve + synthesize | The canonical function of the p53 protein is as a tumor suppressor. | PMID:31897170 | Direct support |
| A1 | Baseline 1 · retrieve + synthesize | The canonical function of the p53 protein is as a tumor suppressor. | PMID:42700791 | Direct support |
| A1 | Agent 1 · planner + retrieve + synthesize | The p53 protein functions as a tumor suppressor. | PMID:42701099 | Direct support |
| A1 | Agent 1 · planner + retrieve + synthesize | The p53 protein functions as a tumor suppressor. | PMID:31897170 | Direct support |
| A1 | Agent 1 · planner + retrieve + synthesize | The p53 protein functions as a tumor suppressor. | PMID:31792264 | Direct support |
| A2 | Baseline 1 · retrieve + synthesize | BRCA1 is a gene associated with breast and ovarian cancer risk. | PMID:42530926 | Direct support |
| A2 | Baseline 1 · retrieve + synthesize | BRCA1 regulates cellular processes involving DNA damage repair in glioblastoma cells. | PMID:42695496 | Direct support |
| A2 | Agent 1 · planner + retrieve + synthesize | BRCA1 is involved in cellular processes such as DNA damage repair, cell proliferation, and apoptosis. | PMID:42695496 | Direct support |
| B1 | Baseline 1 · retrieve + synthesize | This interaction leads to weakened anti-tumor immune response by inhibiting Type I interferon (IFN-I) production. | PMID:42700791 | Direct support |
| B1 | Agent 1 · planner + retrieve + synthesize | This blockage inhibits Type I interferon (IFN-I) production, leading to a weakened anti-tumor immune response. | PMID:42700791 | Direct support |
| C1 | Baseline 1 · retrieve + synthesize | Pathogenic mutations in PALB2 significantly increase lifetime cancer risk, particularly breast and pancreatic cancers. | PMID:42689189 | Direct support |
| C1 | Baseline 1 · retrieve + synthesize | BRCA1 has an intrinsically disordered region crucial for interactions with proteins such as RAD50, RAD51, MYC, and RB. | PMID:42693354 | Direct support |
| C1 | Agent 1 · planner + retrieve + synthesize | PALB2 mutations have a more dominant pattern of inheritance compared to BRCA1 mutations. | PMID:42689189 | Direct support |
| C1 | Agent 1 · planner + retrieve + synthesize | BRCA1 is associated with breast and ovarian cancers, while PALB2 is primarily associated with breast and pancreatic cancers. | PMID:42683001 | Direct support |
| E1 | Baseline 1 · retrieve + synthesize | The DNA-repair effector proteins named in the corpus include RAD51, BLM, WRN, RAD50, MYC, and RB. | PMID:42678585 | Direct support |
| E1 | Baseline 1 · retrieve + synthesize | The DNA-repair effector proteins named in the corpus include RAD51, BLM, WRN, RAD50, MYC, and RB. | PMID:42693354 | Direct support |
| E1 | Agent 1 · planner + retrieve + synthesize | The DNA-repair effector proteins named in the passage include RAD51, BLM, and WRN. | PMID:42678585 | Direct support |
| F1 | Baseline 1 · retrieve + synthesize | There is no agreement or consensus on this finding in the literature. | PMID:42642214 | Direct support |
| F1 | Agent 1 · planner + retrieve + synthesize | There is ongoing re-evaluation of breast cancer incidence after ovarian cancer in BRCA1/2 carriers. | PMID:42642214 | Direct support |
| G1 | Baseline 1 · retrieve + synthesize | DDIAS plays a critical and evolutionarily conserved role in limiting DNA damage specifically in neural progenitor cells. | PMID:42636811 | Direct support |
| G1 | Baseline 1 · retrieve + synthesize | The management of menopausal symptoms in healthy women carrying BRCA1 or BRCA2 mutations is clinically challenging, particularly in those undergoing risk-reducing salpingo-oophorectomy. | PMID:42575068 | Direct support |
| G1 | Baseline 1 · retrieve + synthesize | The p53 tumor suppressor protein is a transcription factor that plays a prominent role in protecting cells from malignant transformation. | PMID:31665549 | Direct support |
| G1 | Baseline 1 · retrieve + synthesize | Halvade Somatic is a framework for somatic variant calling from DNA sequencing data that reduces runtime significantly compared to the original pipeline. | PMID:35022699 | Direct support |
| G1 | Baseline 1 · retrieve + synthesize | Recent advances in molecular diagnostics show that lesions affecting both copies of the gene for tumor suppressor protein 53 (TP53) count among the most powerful predictors for high-risk disease in multiple myeloma (MM). | PMID:31792264 | Direct support |
| G1 | Agent 1 · planner + retrieve + synthesize | DDIAS plays a role in limiting DNA damage specifically in neural progenitor cells. | PMID:42636811 | Direct support |
| G1 | Agent 1 · planner + retrieve + synthesize | BRCA1 functions as an obligate heterodimer with BARD1 to coordinate accurate DNA repair. | PMID:42693354 | Direct support |
| G1 | Agent 1 · planner + retrieve + synthesize | BARD1 is the obligate binding partner of BRCA1 and plays a critical role in maintaining genome integrity. | PMID:42678585 | Direct support |
| D1 | Baseline 1 · retrieve + synthesize | The BRCA1-BARD1 complex stimulates long-range DNA end resection during homologous recombination. | PMID:42678585 | Direct support |
| D1 | Baseline 1 · retrieve + synthesize | The BRCA1-BARD1 complex coordinates accurate DNA repair. | PMID:42693354 | Direct support |
| A3 | Baseline 1 · retrieve + synthesize | The BRCA1 gene is the main cause of familial forms of breast cancer. | PMID:42676320 | Direct support |
| A3 | Agent 1 · planner + retrieve + synthesize | The BRCA1 gene is the main cause of familial forms of breast cancer. | PMID:42676320 | Direct support |
| B2 | Baseline 1 · retrieve + synthesize | The general premise of the therapeutic approach using PARP inhibitors is that HRD leads to defective DNA repair, making cancer cells more susceptible to PARP inhibitors which further impair their ability to repair DNA damage. | PMID:42648415 | Direct support |
| B2 | Agent 1 · planner + retrieve + synthesize | Poly(ADP-ribose) polymerase (PARP) inhibitors exploit homologous recombination deficiency (HRD) in BRCA-associated ovarian and breast cancers. | PMID:42649993 | Direct support |
| B2 | Agent 1 · planner + retrieve + synthesize | The general premise of exploiting HRD in BRCA-associated cancers involves the use of PARP inhibitors to further impair DNA repair mechanisms in cancer cells. | PMID:42683001 | Indirect support |
| E2 | Baseline 1 · retrieve + synthesize | BRCA2 supports the homologous recombination repair process. | PMID:42652125 | Direct support |
| E2 | Baseline 1 · retrieve + synthesize | The loss of BRCA2 creates a specific drug-treatable vulnerability that is exploited by PARP inhibitors. | PMID:42656272 | Indirect support |
| E2 | Agent 1 · planner + retrieve + synthesize | The loss of BRCA2 creates a vulnerability that is exploited by PARP inhibitors. | PMID:42652125 | Direct support |
| A4 | Baseline 1 · retrieve + synthesize | The investigational drug inavolisib is described being trialed for PIK3CA-mutated endometrial cancer. | PMID:42701058 | Direct support |
| A4 | Agent 1 · planner + retrieve + synthesize | The investigational drug inavolisib is described being trialed for the treatment of PIK3CA-mutated endometrial cancer. | PMID:42701058 | Direct support |
| C2 | Baseline 1 · retrieve + synthesize | elPrep 5 addresses stages such as PCR and optical duplicate marking, sorting by coordinate order, base quality score recalibration, and variant calling. | PMID:33539352 | Direct support |
| C2 | Baseline 1 · retrieve + synthesize | SynthDNM addresses the stage of variant-calling pipelines by constructing simulated training examples from real data. | PMID:33821956 | Direct support |
| C2 | Agent 1 · planner + retrieve + synthesize | elPrep 5 includes steps such as PCR and optical duplicate marking, sorting by coordinate order, base quality score recalibration, and variant calling using the haplotype caller algorithm. | PMID:33539352 | Direct support |
| C2 | Agent 1 · planner + retrieve + synthesize | SynthDNM predicts de novo SNPs and indels with robust accuracy across multiple methods of variant calling. | PMID:33821956 | Direct support |
| B3 | Baseline 1 · retrieve + synthesize | FVC was validated on variants generated from four popular variant callers, showing consistent performance as the best method. | PMID:36114280 | Direct support |
| B3 | Agent 1 · planner + retrieve + synthesize | FVC removes more false variants than current state-of-the-art filtering methods and recalls a higher proportion of true variants. | PMID:36114280 | Direct support |
| T1 | Baseline 1 · retrieve + synthesize | MDM2 promoter competes with HERC2 for binding of oligomeric, phosphorylated, and acetylated p53. | PMID:31665549 | Direct support |
| T1 | Agent 1 · planner + retrieve + synthesize | MDM2 promoter competes with HERC2 for binding of oligomeric, phosphorylated, and acetylated p53. | PMID:31665549 | Direct support |
| G3 | Baseline 1 · retrieve + synthesize | The GH-IGF axis is involved in cancer biology. | PMID:42705172 | Direct support |
| G3 | Baseline 1 · retrieve + synthesize | Mutant p53 suppresses the immune system by interacting with TBK1. | PMID:42700791 | Direct support |
| G3 | Baseline 1 · retrieve + synthesize | Single or double hits to TP53 can increase resistance to drugs. | PMID:31792264 | Direct support |
| G3 | Baseline 1 · retrieve + synthesize | EBLN1 regulates DNA double-strand break repair in GBM. | PMID:42695496 | Direct support |
| G3 | Agent 1 · planner + retrieve + synthesize | The GH-IGF axis is involved in various physiological processes, including cancer biology. | PMID:42705172 | Direct support |
| G3 | Agent 1 · planner + retrieve + synthesize | TP53 mutations are associated with cancer progression and immune evasion. | PMID:42700791 | Direct support |
| G3 | Agent 1 · planner + retrieve + synthesize | Mutations in the BRCA1 gene are linked to hereditary breast cancer. | PMID:42676320 | Direct support |
| G3 | Agent 1 · planner + retrieve + synthesize | TP53 mutations are common in breast cancers and result in altered p53 function. | PMID:42701099 | Direct support |
| G3 | Agent 1 · planner + retrieve + synthesize | The p53 tumor suppressor protein is regulated by various molecular mechanisms. | PMID:31665549 | Direct support |
| G4 | Baseline 1 · retrieve + synthesize | Integrin alpha-3 (ITGA3) is associated with breast cancer recurrence and poor clinical outcomes. | PMID:42699527 | Direct support |
| G4 | Baseline 1 · retrieve + synthesize | EBLN1 regulates DNA double-strand break repair in glioblastoma cells by modulating ATM and BRCA1 expression. | PMID:42695496 | Direct support |
| G4 | Agent 1 · planner + retrieve + synthesize | Integrin alpha-3 (ITGA3) is associated with breast cancer recurrence and poor clinical outcomes. | PMID:42699527 | Direct support |
| G4 | Agent 1 · planner + retrieve + synthesize | EBLN1 regulates DNA double-strand break repair in glioblastoma cells by modulating ATM and BRCA1 activity. | PMID:42695496 | Direct support |
| G4 | Agent 1 · planner + retrieve + synthesize | BRCA1 plays a central role in maintaining genome stability through its involvement in DNA damage repair, transcriptional regulation, and cell-cycle control. | PMID:42676320 | Direct support |
| G4 | Agent 1 · planner + retrieve + synthesize | BRCA1 plays a central role in maintaining genome stability through its involvement in DNA damage repair, transcriptional regulation, and cell-cycle control. | PMID:42693354 | Direct support |
| G4 | Agent 1 · planner + retrieve + synthesize | The tumor microenvironment significantly influences the efficacy of PARPi therapy in cancers with homologous recombination deficiency. | PMID:42648415 | Direct support |
| B4 | Agent 1 · planner + retrieve + synthesize | TP53 status is a prognostic marker in childhood acute lymphoblastic leukemia (ALL). | PMID:31897170 | Direct support |
| B4 | Agent 1 · planner + retrieve + synthesize | TP53 status is a predictor for high-risk disease in multiple myeloma (MM). | PMID:31792264 | Direct support |
| C3 | Baseline 1 · retrieve + synthesize | CDK4/6 inhibitors target mechanisms including retinoblastoma-pathway escape and cyclin E-cyclin-dependent kinase 2 (CDK2) activation. | PMID:42698831 | Direct support |
| C3 | Baseline 1 · retrieve + synthesize | PARP inhibitors target DNA repair defects and mechanisms including synthetic lethality, PARP trapping, immune activation, and metabolic reprogramming. | PMID:42648415 | Direct support |
| C3 | Agent 1 · planner + retrieve + synthesize | Both CDK4/6 inhibitors and PARP inhibitors have roles in gynecological cancers. | PMID:42698831 | Direct support |
| C3 | Agent 1 · planner + retrieve + synthesize | Both CDK4/6 inhibitors and PARP inhibitors have roles in gynecological cancers. | PMID:42648415 | Direct support |